阿夫凯泰片 | China Drugs ListAficamten tablets | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- Cytokinetics,IncorporatedCytokinetics, Incorporated
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 心血管Cardiovascular
- 公开来源记录的适应症
- 本品用于治疗纽约心脏协会(NYHA)心功能分级 II-III级的梗阻性肥厚型心肌病(HCM)成人患者,以改善运动能力和症状。Treatment of adults with New York Heart Association (NYHA) functional class II-III obstructive hypertrophic cardiomyopathy (HCM), to improve exercise capacity and symptoms.
- 适应症来源与口径
- 来源日期： 2026. 适应症反映所引用的历史批准范围，不是截至2026年的完整适应症。Source date(s): 2026. Indications reflect the cited historical approval, not the complete indication set as of 2026.
- 说明书信息局限
- 已取得完整官方药品说明书。 现有完整说明书来自海外辖区；尚未取得完整的中国现行说明书。中国适应症另由中国来源支持。Complete official prescribing information obtained. The available full label is from an overseas jurisdiction; a complete current Chinese label remains unavailable. Chinese indications are supported separately by Chinese sources.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 2025国家医保目录未匹配；待人工复核Not matched in the 2025 national list; manual review pending
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保核查说明
- 未在提取的目录中匹配到，并不证明被排除。复方制剂仍需人工复核。No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.